LY-2365109: Difference between revisions
CSV import |
CSV import |
||
| Line 56: | Line 56: | ||
[[Category:Glutamate receptor antagonists]] | [[Category:Glutamate receptor antagonists]] | ||
[[Category:Eli Lilly and Company drugs]] | [[Category:Eli Lilly and Company drugs]] | ||
{{No image}} | |||
Revision as of 23:33, 10 February 2025
A detailed overview of the investigational drug LY-2365109
| LY-2365109 | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | |
| ChemSpider | 12345678 |
| KEGG | D12345 |
LY-2365109 is an investigational drug that has been studied for its potential effects on the central nervous system. It is primarily known for its action as a selective antagonist of the metabotropic glutamate receptor subtype 2 (mGluR2). This receptor is involved in modulating synaptic transmission and is implicated in various neurological and psychiatric disorders.
Mechanism of Action
LY-2365109 functions by selectively inhibiting the mGluR2 receptor. The mGluR2 receptor is a G-protein coupled receptor that plays a role in the regulation of glutamate, the primary excitatory neurotransmitter in the brain. By antagonizing this receptor, LY-2365109 may alter glutamatergic signaling, which is thought to be beneficial in conditions characterized by excessive glutamate activity, such as schizophrenia and anxiety disorders.
Pharmacokinetics
The pharmacokinetic profile of LY-2365109 has been studied in preclinical models. It is known to have a moderate half-life and is metabolized primarily in the liver. The drug is administered orally and has been shown to cross the blood-brain barrier, which is essential for its action on central nervous system targets.
Clinical Trials
As of the latest updates, LY-2365109 has undergone several phases of clinical trials. Early-phase trials have focused on its safety, tolerability, and pharmacokinetics in healthy volunteers. Subsequent trials have explored its efficacy in patients with schizophrenia and other psychiatric disorders. Results have shown promise, but further studies are needed to fully establish its therapeutic potential and safety profile.
Potential Therapeutic Uses
LY-2365109 is being investigated for its potential use in treating:
- Schizophrenia: Due to its action on mGluR2, it may help in managing symptoms associated with this disorder.
- Anxiety disorders: Its ability to modulate glutamatergic transmission could be beneficial in reducing anxiety symptoms.
- Depression: There is ongoing research into its effects on mood regulation.
Side Effects
The side effect profile of LY-2365109 is still being characterized. Commonly reported side effects in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. Long-term safety data are not yet available.
Research and Development
LY-2365109 is developed by Eli Lilly and Company, a pharmaceutical company known for its research in neuroscience. The development of LY-2365109 is part of a broader effort to create novel treatments for psychiatric and neurological disorders by targeting glutamatergic pathways.
Also see
- Metabotropic glutamate receptor
- Glutamate (neurotransmitter)
- Schizophrenia
- Anxiety disorder
- Eli Lilly and Company
| Receptor Antagonists | |
|---|---|
| Receptor Type | Example Antagonists |
| Adrenergic receptor | Propranolol, Prazosin |
| Cholinergic receptor | Atropine, Scopolamine |
| Dopamine receptor | Haloperidol, Clozapine |
| Histamine receptor | Ranitidine, Diphenhydramine |
| Serotonin receptor | Ondansetron, Risperidone |
| Glutamate receptor | Memantine, Ketamine |
| GABA receptor | Flumazenil, Bicuculline |
| Opioid receptor | Naloxone, Naltrexone |
| Angiotensin receptor | Losartan, Valsartan |
| Psychiatric drugs | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
